Sepsis: Broad-spectrum PCR-Test receives CE-IVD approval
Groundbreaking test enables rapid and reliable routine diagnostics
Sepsis (coll. blood poisoning) is a systemic inflammation of the whole body ultimately leading to multiple organ dysfunctions. Even though the latest intensive care technology can maintain organ function in critical phases for some time, sepsis is an extremely severe prognosis. Despite greatest efforts, septicemic patients today still have a mortality rate of 30-50%. Several researchers have estimated that, in the U.S. alone, more than 580 patients die from sepsis every day. The survival rate greatly depends on an early therapy including targeted antibiotic treatment.
Today, sepsis-causing pathogens are usually identified by a traditional microbiological method: the so-called blood culture. Blood culture tests normally deliver results after 2 to 5 days and, in some cases, the analysis takes even longer. Moreover, blood cultures are limited when detecting fastidious organisms or when antibiotic therapies have already been administered. Therefore, molecular biologists have been working for quite some time on rapid sepsis screening technologies. In contrast to other molecular tests, the broad-spectrum SepsiTest™ detects all relevant pathogens and, thus, for the first time enables very targeted antibiotic therapies. Latest research from SepNet, the European sepsis network, showed dramatically increased survival rates for sepsis patients receiving early and targeted antibiotic treatments.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.